Home › Upcoming votes › Summit Therapeutics Inc.
This meeting took place on November 4, 2026. Official results not yet filed. Companies report them on Form 8-K, usually within four business days of the meeting; they will appear here and on the company page once they have been read.
The deadline as the proxy statement states it: “vote via the Internet, telephone or mail, your vote must be received by 11:59 p.m. Eastern Time, on November 3, 2026”. Shares held through a bank, a broker or a company plan can have a different deadline; the voting instruction form says.
Read the proxy statement on EDGARSummit Therapeutics Inc.: past votes
Ballot read from the proxy statement and checked. As listed in Summit Therapeutics Inc.’s proxy statement, with the board’s recommendation on each item.
| # | Item | Proposed by | Board recommends | Last year (same kind of item) |
|---|---|---|---|---|
| 1 | AMENDMENT TO THE CHARTER TO INCREASE THE AUTHORIZED NUMBER OF SHARES OF COMMON STOCK | Board | For | — |
From Summit Therapeutics Inc.’s Form 8-K, filed June 17, 2025, for the meeting held June 12, 2025 (read it on EDGAR). Support is the share of votes cast that were FOR: abstentions and broker non-votes are left out.
| Item | Support (of votes cast) | Reported outcome |
|---|---|---|
| Elect Director: Robert W. Duggan | 99.9% | — |
| Elect Director: Mahkam Zanganeh | 99.9% | — |
| Elect Director: Manmeet Soni | 99.9% | — |
| Elect Director: Kenneth A. Clark | 99.9% | — |
| Elect Director: Robert Booth | 99.9% | — |
| Elect Director: Alessandra Cesano | 99.9% | — |
| Elect Director: Yu (Michelle) Xia | 99.9% | — |
| Elect Director: Mostafa Ronaghi | 99.9% | — |
| Elect Director: Jeff Huber | 99.9% | — |
| Ratification of the appointment of PricewaterhouseCoopers LLP | 99.9% | — |
| Advisory vote to approve the compensation of named executive officers | 97% | — |
The five managers that reported the most shares voted at Summit Therapeutics Inc.’s June 12, 2025 meeting, from their Form N-PX filings. This is how they voted then; it says nothing about how they will vote this time. Every manager’s vote.
| Item | T. Rowe Price | Fidelity | Vanguard | Charles Schwab | Aberdeen |
|---|---|---|---|---|---|
| Elect Director: Robert W. Duggan | Against | For | For | For | For |
| Elect Director: Mahkam Zanganeh | Against | For | For | For | For |
| Elect Director: Manmeet Soni | Against | For | For | For | For |
| Elect Director: Kenneth A. Clark | Against | Mixed | For | Against | Against |
| Elect Director: Robert Booth | For | For | For | For | For |
| Elect Director: Alessandra Cesano | For | For | Against | For | For |
| Elect Director: Yu (Michelle) Xia | Against | For | For | For | Against |
| Elect Director: Mostafa Ronaghi | For | Mixed | For | For | For |
| Elect Director: Jeff Huber | For | For | For | For | For |
| Ratification of the appointment of PricewaterhouseCoopers LLP | For | For | For | For | For |
| Advisory vote to approve the compensation of named executive officers | Against | Against | For | For | Against |
The meeting facts and ballot come from the SEC proxy filings listed above. Ballots are read from the proxy statement and checked against the filing’s own text; when that check does not pass, the page shows “see the proxy statement” instead of a ballot. Last year’s figures are the company’s official Form 8-K results and the managers’ Form N-PX reports. Nothing on this page predicts how any shareholder will vote, and it is not investment advice. How this works.